NEJM Interview: Dr. Gil Rabinovici on the FDA’s controversial approval of a new treatment for Alzheimer’s disease.
Aug 25, 2021
16:39
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr. Gil Rabinovici is a professor of neurology at the University of California, San Francisco. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. G.D. Rabinovici. Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab. N Engl J Med 2021;385:771-774. G.C. Alexander and Others. Revisiting FDA Approval of Aducanumab. N Engl J Med 2021;385:769-771.
NEJM Interviews